Search

A study conducted by Yangzhou University in Jiangsu, China, explored the experiences of Chinese young adults with low-risk papillary thyroid cancer in shared decision-making processes. The study involved interviews with 24 patients, revealing challenges in information sharing, reasons for seeking information, and factors influencing decision-making. The findings suggest the importance of flexible strategies to support collaborative treatment decision-making in the context of doctor-patient interactions for low-risk papillary thyroid cancer. The research emphasizes the need for clinicians to inquire about patients' role preferences, provide details on treatment options, and encourage patients to share their preferences and concerns. [Extracted from the article]

Researchers from the Department of Thyroid and Breast Surgery in Anhui, China, have conducted a study on multifocal papillary thyroid carcinoma (MPTC). The study found that MPTC cases can be classified into two clonal origins: intraglandular metastatic and independent multicentric origin. Differences were observed in gene mutations, protein expression, and tumor invasiveness between the two groups. The research suggests that surgical approaches and follow-up strategies for intraglandular metastatic MPTC should be aggressive and individualized. [Extracted from the article]

The article discusses a study on the potential use of bitter taste receptor agonists to induce apoptosis in papillary thyroid cancer cells. The research found that activation of these receptors led to decreased cell viability and increased apoptosis in the cancer cells. Higher expression of a specific bitter taste receptor gene, TAS2R14, was associated with better progression-free survival in patients, suggesting a potential therapeutic relevance in managing thyroid cancer. The study highlights the importance of exploring alternative treatment options for thyroid cancer based on the activation of taste receptors. [Extracted from the article]

Researchers at the First Affiliated Hospital of Chongqing Medical University conducted a study comparing the clinical features of papillary thyroid cancer (PTC) with and without Hashimoto's thyroiditis (HT). The study included 200 patients, with findings suggesting that HT may have an inhibitory role in the occurrence of PTC and could be a protective factor. Women were found to be more susceptible to PTC or PTC with HT than men, and patients under 55 years old accounted for a larger proportion in the PTC + HT group. The study provides valuable insights into the relationship between HT and PTC, highlighting potential implications for patient care and treatment. [Extracted from the article]

A recent study from the University of Padua highlights the anti-proliferative and anti-migratory effects of licorice extract and glycyrrhetinic acid on papillary thyroid cancer cell cultures. Licorice, containing over 300 active compounds, shows promise in inhibiting cancer growth. The research found that glycyrrhetinic acid increased apoptosis rates in cell lines, while licorice extract induced oxidative stress. This study provides valuable insights into potential treatments for papillary thyroid cancer. [Extracted from the article]

A recent study from Yonsei University College of Medicine in Seoul, South Korea, focused on enhancing treatment efficacy in lenvatinib-resistant papillary thyroid cancer. The research aimed to identify small-molecule SERCA inhibitors to target drug-resistant cancers effectively. The study found that two SERCA inhibitors showed promise in reducing cell viability in patient-derived lenvatinib-resistant PTC cells when used in combination with lenvatinib, offering potential clinical value for new combination therapies. The findings were published in the International Journal of Molecular Sciences. [Extracted from the article]

A recent study conducted in Bydgoszcz, Poland, explored the expression patterns of claudin-1 and claudin-4 in thyroid pathologies and their potential links to thyroid cancer. The researchers analyzed 162 thyroid samples from patients with various thyroid conditions and found that claudin-1 and claudin-4 were overexpressed in papillary thyroid cancer compared to normal thyroid tissues. High expression of claudin-1 was associated with lower 5-year overall survival rates in patients with papillary thyroid cancer. The study suggests that targeting claudins may have therapeutic potential in thyroid cancer treatment, but further trials are needed for clinical implementation. [Extracted from the article]

A recent study from the European Institute of Oncology in Milan, Italy, explores the role of central neck dissection (CND) in the treatment of papillary thyroid cancer (PTC). The study analyzed data from 657 patients who underwent surgery for PTC, including CND, between 1998 and 2021. The study found that CND can lead to high disease-free survival rates and help identify patients who may benefit from additional treatment. However, the study also noted that a bilateral approach to CND can result in a significant risk of permanent hypoparathyroidism. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Chongqing Medical University aimed to develop a predictive model for paratracheal lymph node metastasis (PLNM) in patients with clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC). The researchers compared traditional nomograms with machine learning (ML) models and found that ML models, particularly the XGBoost model, outperformed the traditional nomogram in predicting PLNM. The study concluded that ML is a reliable tool for predicting PLNM in cN0 PTC patients, and the resulting web-based calculator can assist in surgical planning for paratracheal lymph node dissection. [Extracted from the article]

A recent study conducted by researchers at Central South University explores the role of ATAD2 (ATPase Family AAA Domain-Containing 2) in thyroid cancer. The study analyzed the expression and alteration profiles of ATAD2 in various tumor types and its relationship with immune infiltration. The results showed that ATAD2 is overexpressed in most cancers and is associated with poor prognosis. In papillary thyroid carcinoma (PTC), ATAD2 promotes cell proliferation, migration, and invasion by activating the PI3K-AKT pathway. The study suggests that ATAD2 could serve as a biomarker for pan-cancer diagnosis and prognosis, as well as a predictor of immunotherapeutic responsiveness and a potential therapeutic target. [Extracted from the article]

A recent study conducted by Zhejiang University in China investigated the relationship between preoperative serum lipids levels and the outcomes of patients with papillary thyroid cancer (PTC). The study found that low levels of triglyceride (TAG) and high-density lipoprotein (HDL) were independently associated with a higher risk of recurrence in PTC. The researchers developed a nomogram model that showed clinical predictive value for disease-free survival. These findings suggest that preoperative serum lipid concentrations can be helpful in predicting the prognosis for patients with PTC. [Extracted from the article]

Researchers at Anhui Medical University in China have conducted a study on the relationship between central lymph node metastasis (CLNM) and lateral lymph node metastasis (LLNM) in patients with papillary thyroid carcinoma (PTC). The study aimed to investigate the predictive ability of CLNM regarding LLNM and its impact on the prognosis of patients with thyroid cancer. The results showed a significant association between the central lymph node ratio (CLNR), the number of positive central lymph nodes, and LLNM in patients with sonographically suspected lateral lymph nodes. This information may assist physicians in making personalized clinical decisions for patients with PTC. [Extracted from the article]

A researcher from the National Taipei University of Nursing and Health Sciences has published new data on thyroid cancer. The study focused on papillary thyroid carcinoma (PTC), which is the most common type of thyroid cancer. The research found a close relationship between the levels of free thyroxine (FT4) and thyroid-stimulating hormone (TSH) and the incidence of lymph node metastasis (LNM) in PTC patients. The findings suggest that FT4 and TSH levels could be used as predictive factors for LNM in PTC, which could help guide treatment decisions and patient counseling. [Extracted from the article]

A study conducted by Shanghai Jiao Tong University in China analyzed the genetic profile and clinicopathologic features of locally advanced papillary thyroid cancers (LAPTC). The study found that the main mutation in LAPTC is the BRAF(V600E) mutation, followed by TERT promoter mutations. Synergetic mutations of BRAF(V600E) and TERT promoters were associated with aggressive clinicopathologic features and an increased risk of recurrence and mortality. The findings of this study may help predict the aggressive behavior of LAPTC and assist in clinical decision-making. [Extracted from the article]

A recent study conducted at the National Institute of Oncology in Budapest, Hungary, examined the correlation between PD-L1 (programmed death ligand 1) and NIS (sodium/iodide symporter) expression in primary tumor samples of lymph node metastatic papillary thyroid carcinoma (PTC). The researchers analyzed the expression of PD-L1 and NIS using immunohistochemistry and found no correlation between the two. The study suggests that manipulating the PD-1/PD-L1 axis using antibodies could potentially reinstate the functional expression of NIS. However, the study concludes that there is no correlation between the percentage of NIS- or PD-L1-expressing tumor cells in the primary tumor of lymph node metastatic PTC. [Extracted from the article]

A recent report from Yashoda Hospital discusses the rare occurrence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) in the same patient. The report describes the case of a 36-year-old male who presented with symptoms of headache, palpitations, and abdominal pain. After evaluation, the patient was found to have bilateral pheochromocytoma and MTC, as well as a RET proto-oncogene germline mutation. The patient underwent bilateral adrenalectomy and total thyroidectomy, and genetic analysis revealed a high-risk RET mutation. The report emphasizes the importance of early identification through genetic screening and prophylactic total thyroidectomy to prevent complications of aggressive MTC. [Extracted from the article]

A research report from Wuhan University in Hubei, China, explores the identification of potential biomarkers for papillary thyroid carcinoma (PTC) using comprehensive bioinformatics analysis. The study analyzed gene expression profiles and conducted enrichment analyses to identify differentially expressed genes (DEGs) associated with PTC. The research identified 30 key target genes and found that the expressions of ANK2, TLE1, and TCF4 were down-regulated in PTC compared to normal thyroid tissues. These differential genes are expected to serve as reliable molecular markers for the study and diagnosis of PTC. The research was supported by the National Natural Science Foundation of China. [Extracted from the article]

A patent application titled "A Method To Identify Exceptional Anti-Tumor Benefit From Braf Targeted Therapies" has been published online. The inventor, Hans Ragnar Widlund, proposes a method for determining whether a cancer patient is likely to benefit from treatment with a BRAF inhibitor. The method involves evaluating the presence and level of GAPDHS in a sample of cancer cells and comparing it to a reference level. If the level of GAPDHS is equal to or greater than the reference level, there is a high likelihood of response to the treatment. The patent application also includes methods for treating cancer patients who have been identified as likely to benefit from BRAF inhibitors. The invention aims to personalize precision medicines for improved cancer care. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Wenzhou Medical University in China aimed to develop a simple and cost-effective method for accurately diagnosing thyroid nodules as either malignant or benign. The study included 86 patients with papillary thyroid cancer and 29 benign cases. The researchers used radiomics and molecular biomarkers to establish diagnostic models, and found that a combination of four genes and clinical data resulted in a successful diagnostic panel for the eastern population. The study provides valuable insights into improving diagnostic ability in papillary thyroid cancer. [Extracted from the article]

Researchers from Kuwait University have conducted a study on papillary thyroid cancer (PTC) and its association with mitochondrial DNA (mtDNA) copy number. The study found that the relative mtDNA copy number was significantly higher in PTC patients compared to control thyroid tissues. The risk of developing PTC also increased with higher mtDNA copy number tertiles. The study suggests that mtDNA copy number may serve as a potential biomarker for predicting the risk of PTC. [Extracted from the article]

A recent study conducted by researchers at the University of Texas MD Anderson Cancer Center has found that the thyroid differentiation score (TDS) may serve as a potential prognostic biomarker in papillary thyroid carcinoma (PTC), particularly in BRAFV600E-mutated tumors. The study analyzed two independent cohorts of PTC patients and found that higher TDS was associated with longer progression-free interval (PFI) and overall survival (OS) in the MD Anderson cohort. These findings suggest that TDS could be used to quantify differentiation status and predict survival outcomes in PTC patients. Further research is needed to validate these results and explore the clinical implications of TDS in thyroid cancer treatment. [Extracted from the article]

A study conducted by researchers at Sichuan University aimed to improve the risk prediction for patients with papillary thyroid cancer (PTC). The researchers developed two predictive models based on comprehensive clinical data from a cohort of 2539 patients. These models, which incorporated lymph node features and preablation stimulated thyroglobulin (s-Tg), outperformed the existing risk stratification system in predicting structural incomplete response (SIR) at the one-year follow-up visit. The study concluded that the inclusion of lymph node features and s-Tg has the potential to enhance the predictive accuracy and clinical utility of the existing risk stratification system for PTC patients. [Extracted from the article]

A recent study conducted by researchers at Aristotle University of Thessaloniki in Greece explores the genetic and epigenetic associations of FOXP3 with papillary thyroid cancer (PTC) predisposition. PTC is the most common type of thyroid malignancy, with a higher incidence in females. The study found that certain genotypes and alleles of the FOXP3 gene were associated with PTC predisposition only in females. Additionally, differences in methylation status were observed in the FOXP3 gene between female PTC patients and controls, which may explain the higher incidence of PTC in females. This research provides valuable insights into the genetic factors contributing to thyroid cancer. [Extracted from the article]

A new study conducted by a researcher at Sichuan University in China has made significant findings on thyroid cancer. The study focuses on predicting lymph node metastasis of papillary thyroid carcinoma (PTC), a type of thyroid cancer. The researcher developed a model called MethyAE, which utilizes DNA methylation data to predict lymph node metastasis with high accuracy. This model could potentially help avoid unnecessary surgeries and guide treatment decisions for PTC patients. The study is the first attempt to predict PTC lymph node metastasis through DNA methylation. [Extracted from the article]

A new study conducted by researchers at Fudan University Shanghai Cancer Center in China explores the impact of lymph node metastasis on the recurrence of papillary thyroid carcinoma (PTC). The study analyzed the medical records of 1,209 patients with stage T1 PTC who underwent thyroidectomy with central lymph node dissection. The researchers found that the lymph node positive ratio (LNPR) was significantly higher in patients who experienced recurrence compared to those who did not. The study suggests that LNPR can be a reliable prognostic indicator for local lymph node recurrence in patients with T1 stage PTC. [Extracted from the article]

A study conducted by researchers at Alborz University of Medical Sciences in Karaj, Iran, focused on identifying risk factors for central cervical lymph node metastasis in patients with papillary thyroid carcinoma. The study analyzed 150 patients and found that capsular invasion, lymphovascular invasion, and involvement of the upper thyroid pole were identified as risk factors for central lymph node involvement. The study concluded that central lymph node dissection is recommended for patients with these risk factors. The research provides valuable insights for the treatment and management of papillary thyroid carcinoma. [Extracted from the article]

A recent study conducted at Linkou Chang Gung Memorial Hospital in Taoyuan, Taiwan, focused on a rare form of thyroid cancer called Carcinoma Showing Thymus-like Differentiation (CASTLE). The researchers found that CASTLE accounts for only 0.1%-0.15% of all thyroid cancers and often involves the extension of tumors to adjacent organs. The study presented a case of a 58-year-old female patient who initially presented with hoarseness and was diagnosed with papillary thyroid carcinoma. However, further examination revealed the presence of CASTLE as well. The researchers concluded that the prognosis for CASTLE is generally favorable, and the treatment differs from other aggressive forms of thyroid cancer. [Extracted from the article]

A recent study conducted by researchers from Fudan University Shanghai Cancer Center in China aimed to identify the risk factors for cervical lymph node metastasis in elderly patients aged 65 and older diagnosed with papillary thyroid cancer (PTC). The study included 328 elderly patients and found that tumor size and multifocality were significant risk factors for central and lateral lymph node metastasis (CLNM/LLNM) in this population. Additionally, male gender, age 70, and microcalcification were identified as crucial predictors for LLNM. The study provides valuable insights into the risk factors associated with lymph node metastasis in elderly PTC patients. [Extracted from the article]

A recent study conducted at Minda Hospital of Hubei Minzu University in China has investigated the effects of dysregulated gene expressions on the prognosis of classical papillary thyroid carcinoma (cPTC). Using expression profiling datasets from the Cancer Genome Atlas (TCGA) database, the researchers identified four differentially expressed genes (DEGs) - SALL3, PPBP, MYH1, and SYNDIG1 - which were used to construct a risk model to predict the prognosis of cPTC patients. The study suggests that this four-gene signature could serve as an independent prognostic biomarker to improve prognosis prediction in cPTC patients older than 46. [Extracted from the article]

A recent report from Weill Cornell Medicine discusses the reporting patterns of aggressive histologic subtypes in papillary thyroid cancer (PTC). The study found that the tall cell, columnar, and diffuse sclerosing subtypes of PTC are increasing in incidence, but there is wide variation in reporting. The majority of these aggressive subtypes were reported by academic facilities, and there was regional variation in reporting. The study also found that aggressive subtypes of PTC are associated with worse outcomes. The researchers suggest further evaluation of environmental or geographic factors in addition to increased awareness and accurate diagnosis of these subtypes. [Extracted from the article]

A new report discusses research findings on thyroid cancer, specifically focusing on the diagnostic accuracy of fine needle aspiration cytology (FNAC) and thyroglobulin (Tg) in assessing metastatic lymph nodes (LNs) in thyroid cancer. The study aimed to find a reliable biomarker to improve the accuracy of FNAC in diagnosing metastatic LNs in patients with papillary thyroid cancer (PTC). The researchers examined 99 LNs from PTC patients and found that washout CYFRA 21-1 demonstrated higher diagnostic sensitivity and accuracy compared to Tg and FNAC. The study suggests that FNAC plus washout CYFRA 21-1 may be a novel solution for diagnosing metastatic LNs in PTC. [Extracted from the article]

A recent report from Aarhus University Hospital compares the quality of clinical practice guidelines for papillary thyroid cancer in Scandinavian countries (Norway, Denmark, and Sweden) with those of the American Thyroid Association (ATA). The study found that the ATA guidelines had the highest quality, with the Scandinavian guidelines scoring lower in most domains. The researchers suggest that international cooperation in producing guidelines may be beneficial. The full report can be accessed in the British Journal of Surgery. [Extracted from the article]

A recent study conducted at North Sichuan Medical College in Sichuan, People's Republic of China, focused on the role of circular RNA (circRNA) in papillary thyroid carcinoma (PTC), the most common form of thyroid cancer. The researchers investigated the function and mechanism of circ-methyltransferase-like 15 (METTL15) in PTC cells. They found that circ-METTL15 and X-linked inhibitor of apoptosis protein (XIAP) were upregulated in PTC cells, while miR-200c-3p was downregulated. Inhibiting circMETTL15 or increasing miR-200c-3p levels resulted in decreased proliferation, migration, and invasion of PTC cells, as well as increased apoptosis. The study concluded that circ-METTL15 stimulates aggressive behavior in PTC cells by coopting miR-200c-3p/XIAP. [Extracted from the article]

A recent report from the Memorial Sloan-Kettering Cancer Center in New York City provides new insights into the outcomes of conversion surgery for patients with low-risk papillary thyroid carcinoma. The study compared patients who underwent conversion surgery after a period of active surveillance with those who underwent initial surgery. The results showed that there were no significant differences in surgical complications, pathologic characteristics, overall survival, or recurrence-free survival between the two groups. This suggests that active surveillance may be a feasible and safe option for patients with low-risk papillary thyroid carcinoma. [Extracted from the article]

A recent study conducted by researchers at the Universidad Central del Caribe has found that there are ethnic disparities in the expression of the F10 gene in papillary thyroid carcinoma (PTC), a type of thyroid cancer. The study revealed that Hispanic women in the United States have a higher chance of developing advanced PTC compared to non-Hispanic women. The researchers also discovered that low expression of the F10 gene is associated with a higher probability of tumor recurrence and lower disease-free rates in Hispanic patients. These findings highlight the importance of considering ethnic disparities in molecular profiles for understanding cancer susceptibility and developing targeted interventions and treatment strategies for diverse patient populations. [Extracted from the article]

A study conducted at Theagenio Hospital in Thessaloniki, Greece, investigated the significance of Monckeberg sclerosis in patients with papillary thyroid cancer. Monckeberg sclerosis is a form of calcification in the arteries and has been associated with diabetes and renal disease. The study found that the presence of Monckeberg sclerosis did not impact the histological characteristics or aggressiveness of papillary thyroid cancer. The research suggests that Monckeberg sclerosis does not have a prognostic value in thyroid cancer. [Extracted from the article]

A new study from the Pakistan Institute of Medical Sciences discusses a case of a 30-year-old male who presented with a painless swelling in front of his neck. The study highlights the uncommon histopathological finding of papillary thyroid cancer within a thyroglossal duct cyst. The researchers emphasize the importance of appropriate examinations, including neck imaging and fine-needle aspiration cytology, when dealing with rapidly expanding neck masses. The recommended course of action for differentiated thyroid carcinoma is total thyroidectomy. [Extracted from the article]

A recent study conducted by investigators at Washington University in St. Louis, Missouri, examined the molecular characteristics of isthmus papillary thyroid cancers (PTCs) and their potential clinical behavior. The researchers analyzed data from the Cancer Genome Atlas (TCGA) database and found that isthmus PTCs may have a more aggressive gene expression profile compared to lobar/multifocal PTCs. While there were no significant differences in demographic and clinical variables or the frequency of certain mutations between isthmus and non-isthmus PTCs, there was a trend towards increased BRAF mutations in isthmus PTCs. These findings provide a possible molecular explanation for the reported more aggressive behavior of isthmus PTCs. [Extracted from the article]

A recent report from Fudan University Shanghai Cancer Center discusses research on papillary thyroid cancer (PTC) and its recurrence risks. The study conducted an integrative proteogenomic and metabolomic characterization of 102 Chinese PTC patients with different recurrence risks. The research identified molecular factors contributing to different recurrence risks and described the multi-dimensional characteristics of PTC, particularly in metabolism pathways. The study also classified PTC patients into four subtypes based on omics data, highlighting significant differences in clinical factors, prognosis, and potential treatment targets. The findings aim to improve early diagnosis and precision treatment of recurrent PTC. [Extracted from the article]

A recent study conducted by researchers at the University of Wisconsin Madison explores the increase in thyroid cancer incidence in the United States from 1992 to 2018. The study suggests that the rise in incidence is primarily due to the detection of subclinical disease, raising questions about thyroid cancer control. The researchers developed a microsimulation model called PATCAM, which accurately replicated age- and stage-specific thyroid cancer incidence and mortality rates in the United States. This model can be used to identify factors that influence the detection of subclinical thyroid cancers. [Extracted from the article]

A study conducted at Shaheed Beheshti University of Medical Sciences in Tehran, Iran, explored the use of metabolomics to identify biomarkers for distinguishing between papillary thyroid cancer (PTC) and other conditions. The study analyzed plasma samples from 55 patients, including those with PTC, multinodular goiter (MNG), and healthy individuals. The researchers found that the metabolic profile obtained through 1H NMR spectroscopy had the potential to differentiate PTC from healthy plasma, but not from MNG. The study concluded that the observed modifications in plasma metabolites could serve as non-invasive biomarkers for detecting changes in the metabolic profile of thyroid tumors. [Extracted from the article]

A recent study conducted by researchers at Chengdu Medical College in Sichuan, China, explores the efficiency of different diagnostic methods for identifying the BRAF V600E gene mutation in papillary thyroid cancer (PTC). The BRAF gene mutation is commonly found in various types of cancer, including melanoma, colorectal, thyroid, and non-small cell lung cancer. The study highlights the advantages and disadvantages of current detection techniques, aiming to assist clinicians and researchers in selecting the most suitable approach for diagnosing and treating PTC associated with the BRAF gene mutation. The research has been peer-reviewed and published in Experimental and Therapeutic Medicine. [Extracted from the article]

Researchers from the University Hospital Center Sestre Milosrdnice in Zagreb, Croatia have conducted a study on papillary thyroid cancer (PTC) to explore the association between the frequency of BRAF V600E alleles and disease dissemination. The study analyzed 173 PTC samples and found that the presence of the BRAF mutation was significantly linked with angioinvasion, but not with the degree of PTC dissemination. The researchers concluded that the BRAF mutation alone does not significantly contribute to PTC aggressiveness. This information is important for the early identification and treatment of aggressive forms of PTC. [Extracted from the article]

A recent study conducted by researchers at Can Tho University in Vietnam examined the complications associated with neck dissection in patients with papillary thyroid cancer and metastatic lymph nodes. The study analyzed data from 52 patients who underwent total thyroidectomy and lymph node dissection. The results showed that the rates of transient recurrent laryngeal nerve palsy (RLNP) and hypoparathyroidism were high, with rates of 55.8% and 51.9% respectively. The study also found that a greater number of retrieved lymph nodes in the central neck and the addition of lateral neck dissection were predictors for transient RLNP. These findings can help inform preoperative discussions with patients and guide surgeons in minimizing complications during surgery. [Extracted from the article]

A recent study from Lanzhou University in China explores the role of circular RNAs (circRNAs) in papillary thyroid cancer (PTC). PTC is the most common type of thyroid malignancy, and its incidence is increasing globally. The study highlights the potential of circRNAs as diagnostic markers, therapeutic targets, and prognostic indicators for PTC. Dysregulated circRNAs have been found to influence multiple signaling pathways and cellular processes involved in tumorigenesis and metastasis. The research suggests that circRNAs could advance the diagnosis, management, and treatment of PTC. [Extracted from the article]